BLISS GVS PHARMA LIMITED

Scale -

Ebitda is 238 Rs Cr; Annual Growth is 46 %; in Top Quartile; 5 Year CAGR is 12 %
PBT is 75.48 Rs Cr; Annual Growth is 51 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 37 %
PAT is 135 Rs Cr; Annual Growth is 49 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 55 %
Revenue is 927 Rs Cr; Continuous Growth over 3 years; in Top Quartile
Quarterly Revenue is 286 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

PBDIT Margin is 25.62 %; Annual Growth is 27 %; in Top Quartile
PAT Margin is 14.53 %; Annual Growth is 30 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 47 %
Quarterly Ebitda Margin is 27 %; Continuous Growth over 3 Quarters; in Top Quartile
Quarterly Profit margin is 18 %; Continuous Growth over 3 Quarters; in Top Quartile

ROCE is 16.23 %; Annual Growth is 37 %
ROA is 8.65 %; Annual Growth is 33 %; Continuous Growth over 3 years; 5 Year CAGR is 59 %
ROE is 10.82 %; Annual Growth is 35 %; Continuous Growth over 3 years; 5 Year CAGR is 56 %

Debt/Equity is 0; Annual Decline is -100 %; Continuous Decline over 3 years; in Bottom Quartile
Long term Debt is 0 Rs Cr; Annual Decline is -100 %; Continuous Decline over 3 years
Total Debt is 2.93 Rs Cr; Annual Decline is -96 %; Continuous Decline over 3 years; 5 Year CAGR is -59 %
Contingent Liabilities is 29.29 Rs Cr; Annual Decline is -50 %

Change in Inventories/Total Expenses is -3 %; Annual Decline is -147 %; in Bottom Quartile
Exceptional Items/PBT is -1 %; in Bottom Quartile
Current Tax/PAT is 51 %; 5 Year CAGR is -26 %; Continuous Growth over 3 years; in Top Quartile

Operating cashflow/ebitda is 58 %; Continuous Decline over 3 years
Operating cashflow/PAT is 103 %; Continuous Decline over 3 years; 5 Year CAGR is -35 %
Other Expenses/Total Expenses is 25 %; Continuous Growth over 3 years

Sector

Major Subsidiaries/Associates

Key Clients

Products

Product details

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search:

Bliss GVS Pharma ESOP Grant 2026: 2,95,000 Options Issued

Bliss GVS Pharma grants 2,95,000 stock options at Rs. 43 per option

Bliss GVS Pharma Limited (BLISSGVS) share price — eduinvesting

Bliss GVS Pharma Ltd Locks at Upper Circuit With 4.86% Gain — Buyers Queue, Sellers Absent

BLISSGVS: Q2 earnings advanced, with standalone profit including a 4,108.61 lakh impairment reversal

Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers

Bliss GVS Pharma seeks shareholder approval for new ESOP plans